Effects of tranexamic acid on death, disability, vascular occlusive events and other morbidities in patients with acute traumatic brain injury (CRASH-3): a randomised, placebo-controlled trial. (opens new window)

CRASH-3 Trial Collaborators

Source‎: Lancet 2019;394(10210):1713-23.

Indexed‎: PubMed 31623894

DOI‎: 10.1016/S0140-6736(19)32233-0

https://www.ncbi.nlm.nih.gov/pubmed/31623894 (opens new window)

Alternatives to allogeneic platelet transfusion. (opens new window)

Desborough MJ, Smethurst PA, Estcourt LJ, Stanworth SJ.

Source‎: Br J Haematol 2016;175(3):381-92.

Indexed‎: PubMed 27650431

DOI‎: 10.1111/bjh.14338

https://www.ncbi.nlm.nih.gov/pubmed/27650431 (opens new window)

Tranexamic acid: less bleeding and less thrombosis? (opens new window)

Godier A, Roberts I, Hunt BJ.

Source‎: Crit Care 2012;16(3):135.

Indexed‎: PubMed 22748073

DOI‎: 10.1186/cc11374

https://www.ncbi.nlm.nih.gov/pubmed/22748073 (opens new window)

Tranexamic acid for reducing mortality in emergency and urgent surgery. (opens new window)

Perel P, Ker K, Morales Uribe CH, Roberts I

Source‎: Cochrane Database Syst Rev 2013;(1):CD010245.

Indexed‎: PubMed 23440847

DOI‎: 10.1002/14651858.CD010245.pub2

https://www.ncbi.nlm.nih.gov/pubmed/23440847 (opens new window)

The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial. (opens new window)

Roberts I, Shakur H, Afolabi A, Brohi K, Coats T, Dewan Y, Gando S, Guyatt G, Hunt BJ, Morales C, Perel P, Prieto-Merino D, Woolley T; CRASH-2 collaborators.

Source‎: Lancet 2011;377(9771):1096-101, 1101.e1-2.

Indexed‎: PubMed 21439633

DOI‎: 10.1016/S0140-6736(11)60278-X

https://www.ncbi.nlm.nih.gov/pubmed/21439633 (opens new window)

Antifibrinolytic drugs for acute traumatic injury. (opens new window)

Roberts I, Shakur H, Ker K, Coats T; CRASH‐2 Trial collaborators.

Source‎: Cochrane Database Syst Rev 2011;(1):CD004896.

Indexed‎: PubMed 21249666

DOI‎: 10.1002/14651858.CD004896.pub3

https://www.ncbi.nlm.nih.gov/pubmed/21249666 (opens new window)

Use of tranexamic acid to reduce bleeding in burns surgery. (opens new window)

Tang YM, Chapman TW, Brooks P

Source‎: J Plast Reconstr Aesthet Surg 2012;65(5):684-6.

Indexed‎: PubMed 21983540

DOI‎: 10.1016/j.bjps.2011.09.028

https://www.ncbi.nlm.nih.gov/pubmed/21983540 (opens new window)

Tranexamic acid reduced blood transfusions in acute burn surgery: a retrospective case-controlled trial. (opens new window)

Tapking C, Hundeshagen G, Kirchner M, Fischer S, Kneser U, Bliesener B

Source‎: Burns. 2022;48(3):522-28.

Indexed‎: PubMed 35339324

DOI‎: 10.1016/j.burns.2022.03.002

https://pubmed.ncbi.nlm.nih.gov/35339324/ (opens new window)

Salvage use of activated recombinant factor VII in the management of refractory bleeding following cardiac surgery. (opens new window)

Barua A, Rao VP, Ramesh B, Barua B, El-Shafei H.

Source‎: J Blood Med 2011;2:131-4.

Indexed‎: PubMed 22287872

DOI‎: 10.2147/JBM.S21609

https://www.ncbi.nlm.nih.gov/pubmed/22287872 (opens new window)

The treatment of bleeding is to stop the bleeding! Treatment of trauma-related hemorrhage. (opens new window)

Boffard KD, Choong PI, Kluger Y, Riou B, Rizoli SB, Rossaint R, Warren B; NovoSeven Trauma Study Group.

Source‎: Transfusion 2009;49 Suppl 5:240S-7S.

Indexed‎: PubMed 19954486

DOI‎: 10.1111/j.1537-2995.2008.01987.x

https://www.ncbi.nlm.nih.gov/pubmed/19954486 (opens new window)

The early use of fibrinogen, prothrombin complex concentrate, and recombinant-activated factor VIIa in massive bleeding. (opens new window)

Fries D

Source‎: Transfusion 2013;53 Suppl 1:91S-5S.

Indexed‎: PubMed 23301979

DOI‎: 10.1111/trf.12041

https://www.ncbi.nlm.nih.gov/pubmed/23301979 (opens new window)

A Jehovah's Witness with complex abdominal trauma and coagulopathy: use of factor VII and a review of the literature. (opens new window)

Haan J, Scalea T

Source‎: Am Surg 2005;71(5):414-5.

Indexed‎: PubMed 15986972

https://www.ncbi.nlm.nih.gov/pubmed/15986972 (opens new window)

Results of the control trial: efficacy and safety of recombinant activated factor VII in the management of refractory traumatic hemorrhage. (opens new window)

Hauser CJ, Boffard K, Dutton R, Bernard GR, Croce MA, Holcomb JB, Leppaniemi A, Parr M, Vincent JL, Tortella BJ, Dimsits J, Bouillon B; CONTROL Study Group.

Source‎: J Trauma 2010;69(3):489-500.

Indexed‎: PubMed 20838118

DOI‎: 10.1097/TA.0b013e3181edf36e

https://www.ncbi.nlm.nih.gov/pubmed/20838118 (opens new window)

Use of recombinant activated factor VII in patients without hemophilia: a meta-analysis of randomized control trials. (opens new window)

Hsia CC, Chin-Yee IH, McAlister VC.

Source‎: Ann Surg 2008;248(1):61-8.

Indexed‎: PubMed 18580208

DOI‎: 10.1097/SLA.0b013e318176c4ec

https://www.ncbi.nlm.nih.gov/pubmed/18580208 (opens new window)

Rescue treatment with recombinant factor VIIa is effective in patients with life-threatening bleedings secondary to major wound excision: a report of four cases. (opens new window)

Johansson PI, Eriksen K, Alsbjørn B

Source‎: J Trauma 2006;61(4):1016-8.

Indexed‎: PubMed 17033583

DOI‎: 10.1097/01.ta.0000239261.48022.f1

https://www.ncbi.nlm.nih.gov/pubmed/17033583 (opens new window)

Use of recombinant activated factor VII in Jehovah's Witness patients with critical bleeding. (opens new window)

Kandane-Rathnayake RK, Isbister JP, Zatta AJ, Aoki NJ, Cameron P, Phillips LE; Australian and New Zealand Haemostasis Registry Steering Committee

Source‎: ANZ J Surg 2013;83(3):155-60.

Indexed‎: PubMed 23035873

DOI‎: 10.1111/j.1445-2197.2012.06285.x

https://www.ncbi.nlm.nih.gov/pubmed/23035873 (opens new window)

Recombinant factor VIIa in trauma patients with the 'triad of death.' (opens new window)

Mitra B, Cameron PA, Parr MJ, Phillips L.

Source‎: Injury 2012;43(9):1409-14.

Indexed‎: PubMed 21345431

DOI‎: 10.1016/j.injury.2011.01.033

https://www.ncbi.nlm.nih.gov/pubmed/21345431 (opens new window)

Low-dose recombinant factor VIIa for trauma patients with coagulopathy. (opens new window)

Stein DM, Dutton RP, Hess JR, Scalea TM.

Source‎: Injury 2008;39(9):1054-61.

Indexed‎: PubMed 18656871

DOI‎: 10.1016/j.injury.2008.03.032

https://www.ncbi.nlm.nih.gov/pubmed/18656871 (opens new window)

Treatment of excessive bleeding in Jehovah's Witness patients after cardiac surgery with recombinant factor VIIa (Novoseven®). (opens new window)

Tanaka KA, Waly AA, Cooper WA, Levy JH.

Source‎: Anesthesiology 2003;98(6):1513-5.

Indexed‎: PubMed 12766668

https://www.ncbi.nlm.nih.gov/pubmed/12766668 (opens new window)

Alternatives to allogeneic platelet transfusion. (opens new window)

Desborough MJ, Smethurst PA, Estcourt LJ, Stanworth SJ.

Source‎: Br J Haematol 2016;175(3):381-92.

Indexed‎: PubMed 27650431

DOI‎: 10.1111/bjh.14338

https://www.ncbi.nlm.nih.gov/pubmed/27650431 (opens new window)

The early use of fibrinogen, prothrombin complex concentrate, and recombinant-activated factor VIIa in massive bleeding. (opens new window)

Fries D

Source‎: Transfusion 2013;53 Suppl 1:91S-5S.

Indexed‎: PubMed 23301979

DOI‎: 10.1111/trf.12041

https://www.ncbi.nlm.nih.gov/pubmed/23301979 (opens new window)

Plasma fibrinogen level on admission to the intensive care unit is a powerful predictor of postoperative bleeding after cardiac surgery with cardiopulmonary bypass. (opens new window)

Kindo M, Hoang Minh T, Gerelli S, Perrier S, Meyer N, Schaeffer M, Bentz J, Announe T, Mommerot A, Collange O, Pottecher J, Cristinar M, Thiranos JC, Gros H, Mertes PM, Billaud P, Mazzucotelli JP

Source‎: Thromb Res 2014;134(2):360-8.

Indexed‎: PubMed 24857189

DOI‎: 10.1016/j.thromres.2014.05.008

https://www.ncbi.nlm.nih.gov/pubmed/24857189 (opens new window)

Combination of recombinant factor VIIa and fibrinogen corrects clot formation in primary immune thrombocytopenia at very low platelet counts. (opens new window)

Larsen OH, Stentoft J, Radia D, Ingerslev J, Sørensen B

Source‎: Br J Haematol 2013;160(2):228-36.

Indexed‎: PubMed 23151086

DOI‎: 10.1111/bjh.12118

https://www.ncbi.nlm.nih.gov/pubmed/23151086 (opens new window)

Strategies to reduce the use of blood products: a European perspective. (opens new window)

Theusinger OM, Felix C, Spahn DR.

Source‎: Curr Opin Anaesthesiol 2012;25(1):59-65.

Indexed‎: PubMed 22113184

DOI‎: 10.1097/ACO.0b013e32834dec98

https://www.ncbi.nlm.nih.gov/pubmed/22113184 (opens new window)

Desmopressin reduces transfusion needs after surgery: a meta-analysis of randomized clinical trials. (opens new window)

Crescenzi G, Landoni G, Biondi-Zoccai G, Pappalardo F, Nuzzi M, Bignami E, Fochi O, Maj G, Calabrò MG, Ranucci M, Zangrillo A

Source‎: Anesthesiology 2008;109(6):1063-76.

Indexed‎: PubMed 19034103

DOI‎: 10.1097/ALN.0b013e31818db18b

https://www.ncbi.nlm.nih.gov/pubmed/19034103 (opens new window)

Alternatives to allogeneic platelet transfusion. (opens new window)

Desborough MJ, Smethurst PA, Estcourt LJ, Stanworth SJ.

Source‎: Br J Haematol 2016;175(3):381-92.

Indexed‎: PubMed 27650431

DOI‎: 10.1111/bjh.14338

https://www.ncbi.nlm.nih.gov/pubmed/27650431 (opens new window)

Desmopressin in treatment of haematological disorders and in prevention of surgical bleeding. (opens new window)

Svensson PJ, Bergqvist PB, Juul KV, Berntorp E

Source‎: Blood Rev 2014;28(3):95-102.

Indexed‎: PubMed 24703870

DOI‎: 10.1016/j.blre.2014.03.001

https://www.ncbi.nlm.nih.gov/pubmed/24703870 (opens new window)

Coagulopathy caused by vitamin K deficiency in critically ill, hospitalized patients. (opens new window)

Alperin JB

Source‎: JAMA 1987;258(14):1916-9.

Indexed‎: PubMed 3656602

DOI‎: 10.1001/jama.1987.03400140078028

https://www.ncbi.nlm.nih.gov/pubmed/3656602 (opens new window)

Vitamin K deficiency and D-dimer levels in the intensive care unit: a prospective cohort study. (opens new window)

Crowther MA, McDonald E, Johnston M, Cook D

Source‎: Blood Coagul Fibrinolysis 2002;13(1):49-52.

Indexed‎: PubMed 11994567

DOI‎: 10.1097/00001721-200201000-00007

https://www.ncbi.nlm.nih.gov/pubmed/11994567 (opens new window)

The use of fibrin sealant in burn operations. (opens new window)

Foster K

Source‎: Surgery 2007;142(4 Suppl):S50-4.

Indexed‎: PubMed 18019939

DOI‎: 10.1016/j.surg.2007.06.026

https://www.ncbi.nlm.nih.gov/pubmed/18019939 (opens new window)

Use of fibrin sealant in thermal injury. (opens new window)

McGill V, Kowal-Vern A, Lee M, Greenhalgh D, Gomperts E, Bray G, Gamelli R

Source‎: J Burn Care Rehabil 1997;18(5):429-34.

Indexed‎: PubMed 9313125

DOI‎: 10.1097/00004630-199709000-00011

https://www.ncbi.nlm.nih.gov/pubmed/9313125 (opens new window)

Perioperative treatment algorithm for bleeding burn patients reduces allogeneic blood product requirements. (opens new window)

Schaden E, Kimberger O, Kraincuk P, Baron DM, Metnitz PG, Kozek-Langenecker S

Source‎: Br J Anaesth 2012;109(3):376-81.

Indexed‎: PubMed 22719014

DOI‎: 10.1093/bja/aes186

https://www.ncbi.nlm.nih.gov/pubmed/22719014 (opens new window)

Transfusion in trauma: why and how should we change our current practice? (opens new window)

Theusinger OM, Spahn DR, Ganter MT.

Source‎: Curr Opin Anaesthesiol 2009;22(2):305-12.

Indexed‎: PubMed 19390257

DOI‎: 10.1097/ACO.0b013e3283212c7c

https://www.ncbi.nlm.nih.gov/pubmed/19390257 (opens new window)

Viscoelastic point-of-care testing to assist with the diagnosis, management and monitoring of haemostasis: a systematic review and cost-effectiveness analysis. (opens new window)

Whiting P, Al M, Westwood M, Ramos IC, Ryder S, Armstrong N, Misso K, Ross J, Severens J, Kleijnen J

Source‎: Health Technol Assess 2015;19(58):1-228.

Indexed‎: PubMed 26215747

DOI‎: 10.3310/hta19580

https://www.ncbi.nlm.nih.gov/pubmed/26215747 (opens new window)